Compare FSBC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | CGEM |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 904.7M |
| IPO Year | 2021 | 2020 |
| Metric | FSBC | CGEM |
|---|---|---|
| Price | $41.96 | $13.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $41.90 | $30.13 |
| AVG Volume (30 Days) | 74.7K | ★ 881.8K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 28.32 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.25 | N/A |
| Revenue Next Year | $12.30 | $5.20 |
| P/E Ratio | $48.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.26 | $5.68 |
| 52 Week High | $42.26 | $16.74 |
| Indicator | FSBC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 42.75 |
| Support Level | $39.93 | $12.41 |
| Resistance Level | N/A | $16.21 |
| Average True Range (ATR) | 1.00 | 0.94 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 78.74 | 11.57 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.